AFREZZA
(Afrezza)ApprovedBiologic
AFREZZA is one of 34 biologic programs targeting Type 1 Diabetes. It is currently in Approved.
1
Indications
4
Total Trials
0
Active Trials
33
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ozempic
Novo NordiskPhase 3
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Diamox
TevaPhase 2
AFREZZA
MMannkind Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 1 Diabetes2 trials
Regulatory
FDA Approval Timeline[4]
Jun 27, 2014
AFREZZA
BLA BLA022472
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Afrezza. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- MMannkind Corporation